The business of veterinary care technology is both a lucrative and an impactful one—animal health company Zoetis brought in $7.8 billion in revenue in 2021 while developing vaccines and treatments for livestock and pets. Zoetis’s geographic footprint is as wide as its technological scope; the company oversees the production of veterinary biodevices and genetic tests from their design to manufacturing while providing services and products to over one hundred countries. In 2017, Zoetis launched its African Livestock Productivity and Health Advancement (ALPHA) Initiative with a grant from the Bill & Melinda Gates Foundation; ALPHA now provides veterinary technology and training resources to veterinarians and farmers in sub-Saharan Africa. The effort addresses food insecurity by giving small farmers the resources and training to sustainably keep livestock healthy. ALPHA currently operates 16 serology labs across Uganda, Nigeria, Tanzania, and Ethiopia. So far, 11 million chickens and over 45,000 cows have been tested for diseases through these labs. Even more important is the educational element of the initiative: In all, 26,000 farmers and veterinarians have been trained in livestock care and an estimated 1.3 million people have been reached through train-the-trainer programs. That education includes “an emphasis on training women,” senior director of sustainability and innovation communications Christina Lood told Fortune. The Zoetis Foundation has also recently focused on empowering America’s small-business dairy farmers to utilize sustainable technology.
Courtesy of Zoetis
Company Information
As of 10/10/2022
Country
U.S.
Headquarters
Parsippany, N.J.
Industry
Pharmaceuticals
CEO
Kristin Peck
Website
Company Type
Public
Ticker
ZTS
Revenues ($M)
$7,776
Profits ($M)
$2,035
Market Value ($M)
$69,420
Employees
12,100
Market value as of Sept. 30, 2022.
Change the World
Impact Segment
Environmental Impact/Economic Opportunity
Sector
Health Care
Prior Year Rank
-
Lists ranking Zoetis